Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy.

ABSTRACT:

Background

Oligoprogression is defined as cancer progression of a limited number of metastases under active systemic therapy. The role of metastasis-directed therapy, using stereotactic body radiotherapy (SBRT), is controversial as is the continuation versus switch of systemic therapy. We report outcomes of oligoprogressive patients after SBRT, and compare those patients that continued or switched their current line of systemic therapy.

Material/methods

We included patients who developed up to 5 progressive extracranial metastases under systemic therapy for any solid organ malignancy and were treated with SBRT to all lesions at our institution between 01/2014 and 12/2019. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method, a

SUBMITTER: Willmann J 

PROVIDER: S-EPMC10907512 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature